| Objective:To investigate the therapeutic effect of recombinant human interferon α2b vaginal effervescent tablets on cervical HPV(human papillomavirus)infection and LSIL(lowgrade squamous intraepithelial lesions).Methods:Select 218 patients receiving treatment in the department of Gynecology outpatient Department of Shandong Provincial Hospital from October 2018 to March 2020 for the research.They were divided into,on one hand,experimental group and control group randomly,and on the other and,HPV group and LSIL group according to the pathological results of cervical biopsy.The experimental group was treated with study drugs according to the prescribed dosage and method,while the control group was only offered observation without treatment.Each patient was visited 5 times within 6 months according to the regulations to observe and analyze the therapeutic effect and safety of the drugs.The therapeutic effect studies include studies on the general population and different stratified populations.Results:A total of 209 cases were analyzed,including 84 in the HPV group and 125 in the LSIL group.(1)In general population:① In the HPV group,the proportion of cured,effective,ineffective and progressive cases was 56.4%vs 41.4%,1.8%vs 6.9%,36.4%vs 48.3%,5.5%vs 3.4%,and the response rate was 58.2%vs 48.3%(experimental group vs control group),with no significant difference in both HPV clearance effect and response rate between these two groups(z=-0.979,P=0.328;x~2=0.752,P=0.490).②In the LSIL group,for the therapeutic effect of HPV infection,the proportion of cured,effective,ineffective and progressive cases were 65.1%vs 45.2%,12.0%vs 11.9%,21.7%vs 40.5%,1.2%vs 2.4%,and the response rate was 77.1%vs 57.1%(experimental group vs control group).Statistically significant differences has been shown in HPV clearance effect and response rate between these two groups(Z=-2.303,P=0.021;x~2=5.335,P=0.021).③ In the LSIL group,for the therapeutic effect of LSIL,the proportion of cured,ineffective and progressive cases were 91.6%vs 64.3%,2.4%vs 31.0%and 6.0%vs 4.8%,respectively(experimental group vs control group).The response rate was the same as the cure rate.The differences in LSIL efficacy and response rate between these two groups were statistically different(Z=-3.512,P=0.000;x~2=14.311,P=0.000).(2)In stratified population:analysis was performed on patients according to age,obesity,marital status,history of cervical surgery,HPV infection status(single/multiple infection,infection subtype,diagnosis time of infection)and cervical inflammation.The HPV clearance effect and LSIL efficacy were significantly improved in patients aged ≤40 years,married,had no previous cervical surgery history,infected by single type HPV except 16/18 type HPV,whose HPV infection diagnosis period ≤6 months,and with normal or mild cervical inflammatory.The HPV cure rate and response rate,LSIL cure rate(response rate was the same as cure rate)were as follows:① Age ≤40 years old:61.3%vs 56.3%,77.4%vs 62.5%,93.5%vs 75.0%,②married:65.7%vs 43.9%,77.6%vs 56.1%,92.5%vs 63.4%,③No previous cervical surgery history:63.3%vs 42.5%,75.9%vs 55.0%,91.1%vs 62.5%,④Single HPV infection:76.5%vs 48.5%,76.5%vs 48.5%,94.1%vs 60.6%,⑤ Other single type HPV infection except 16/18 type:85.7%vs 41.2%,85.7%VS 41.2%,97.1%vs 52.9%,⑥HPV infection diagnosis period ≤ 6 months:64.9%vs 45.9%,78.4%vs 56.8%,91.9%vs 62.2%,normal or mild cervical inflammatory:58.3%vs 52.4%,70.8%vs 61.9%and 91.7%vs 66.7%(experimental group vs control group).Conclusion:Recombinant human interferon α-2b vaginal effervescent tablets can significantly improve HPV clearance and histological negative probability in LSIL patients,which is a reasonable and effective choice with good safety.In this population,patients aged≤40 years,married,had no previous cervical surgery history,infected by single type HPV except 16/18 type HPV,whose HPV infection diagnosis period ≤ 6 months,and with normal or mild cervical inflammatory have a good therapeutic effect. |
PDF Full Text Request